Depomed Launches Lazanda


Signature SupportTM Program offers a full-range of services to simplify coverage support and patient assistance for patients taking

NEWARK, Calif., Oct. 28, 2013 /PRNewswire/ — , Inc. (NASDAQ: DEPO) today announced that it has launched Lazanda® (fentanyl) nasal spray with its newly formed dedicated team of regional sales specialists and the new SignatureTM Support Program. Lazanda is indicated for the management of breakthrough pain in cancer patients (BTPc) 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

“Breakthrough pain is very common among cancer patients, and can be properly managed to reduce the number and severity of episodes and the interference of daily activities,” said Dr. Emil Annabi, Director of Pain Management and Assistant Professor of Anesthesiology at the University of Arizona, Tucson. “Studies show that breakthrough pain is associated with poorer function and higher cost of care, which is why cancer patients need support services so they can focus on getting pain relief and not be troubled by reimbursement and access issues.”

Depomed’s new Signature Support Program is designed to streamline patient access to Lazanda. Enrollment in the program is simple and easy for patients.  The service provides one-on-one support for healthcare professionals and their patients by offering several services, including:

•Benefit verification and prior authorization facilitation

•Reimbursement assistance with co-pay support

•Eligibility for up to one-month free trial of Lazanda

•1-800 reimbursement support hotline

•Monthly patient prescription reminders

“We recognize that patients with breakthrough cancer pain face many challenges, including reimbursement and access issues,” said Jim Schoeneck President and CEO of Depomed, Inc “With the new Signature Support Program, patients can take…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS